This is the text extract for Applications received since 1 November 2008 , browse documents here.
Applications received for new investments since 1 November 2008 Details of Funding Applications received are published on PHARMAC’s website, in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees 2008. Applications Received Since November 2008 Chemical (Trade) names Varenicline (Champix) Erlotinib (Tarceva) Losartan Gefitinib (Iressa) Rosuvastatin (Crestor) Etanercept (Enbrel) Palivizumab (Syngagis) Cyclosporin Travoprost/timolol (Duotrav) Deferiprone (Ferriprox) Gluten free foods Folic Acid
A314262 - qA14400
Indication Smoking cessation Non small-cell lung cancer Review of Special Authority criteria for congestive heart failure or hypertension Non small-cell lung cancer Hyperlipdaemia Severe chronic plaque psoriasis Respiratory syncytial virus Amendment of SA for steroid resistant nephrotic syndrome Glaucoma Iron overload in thalassaemia major patients Amendment to SA biopsy requirement Prevention of neural tube defects
Applicant Pfizer Astra Zeneca AstraZeneca AstraZeneca AstraZeneca Wyeth Waikato DHB Individual Alcon Orphan Individual Ministry of Health
Date Received 5/12/2008 5/12/2008 8/12/2008 8/12/2008 9/12/2008 9/12/2008 9/12/2008 9/12/2008 5/12/2008 9/12/2008 9/12/2008 9/12/2008
Chemical (Trade) names Gemcitabine (Gemzar) Paliperidone (Invega) Olanzapine (Zyprexa Adhera) Buprenorphine (Norspan) Sitagliptin (Januvia) Sitagliptin and metformin (Janumet) Riluzole (Rilutek) Sorafenib (Nexavar) Thalidomide (Thalidomide Pharmion) Budesonide (Entocort) Lenalidomide (Revlimid) Vildagliptin (Galvus) Aliskirin (Rasilez) Cox-2 inhibitors Ambrisentan (Volibris)
A314262 - qA14400
Indication Pancreatic cancer Schizophrenia Schizophrenia Moderate to severe pain Type 2 diabetes mellitus Type 2 diabetes mellitus Amyotrophic lateral sclerosis Hepatocellular carcinoma Multiple Myeloma Chron’s disease Multiple Myeloma Type 2 diabetes mellitus Hypertension Pain Pulmonary arterial hypertension
Applicant New Zealand Association of Cancer Specialists Janssen-Cilag Eli Lilly Mundipharma Merck Sharp & Dohme Merck Sharp & Dohme Sanofi-Aventis Bayer Celgene New Zealand Society of Gastroenterology Celgene Novartis Novartis New Zealand Haemophilia Treaters Group Glaxo
Date Received 11/12/2008 11/03/2009 6/03/2009 9/03/2009 20/04/2009 20/04/2009 28/05/2009 8/06/2009 11/06/2009 11/06/2009 12/06/2009 12/06/2009 16/06/2009 16/06/2009 17/06/2009
Chemical (Trade) names Insulin glulisine (Apidra) Gluten free multi-seed bread mix Etravirine (Intelence) Rivaroxaban (Xarelto) Budesonide/eformoterol (Symbicort Turbuhaler) Sunitinib (Sutent)
Indication Type 1 and 2 diabetes Gluten intolerance Antiretroviral for HIV Venous thromobembolism prophylaxis. Asthma Advanced renal cell carcinoma
Applicant Sanofi Aventis Bakels Janssen-Cilag Bayer AstraZeneca Pfizer Gastrointestinal Cancer Special Interest Group of the New Zealand Association of Cancer Specialists Individual
Date Received 15/06/2009 1/07/2009 03/09/2009 09/09/2009 15/09/2009 15/09/2009
Gemcitabine (Gemzar)
Pancreatic cancer
15/09/2009
Dornase alpha
Cystic fibrosis
15/09/2009
A314262 - qA14400
Metadata
Title
Applications received since 1 November 2008
Abstract
Applications received for new investments since 1 November 2008 Details of Funding Applications received are published on PHARMAC’s website, in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees 2008. Applications Received…
Page 1
Note
This text has been extracted from the source PDF document.
Also available as plain text.
Please contact webmaster to discuss alternative format options.
